Slide 1: The innovation engine for a better tomorrow
The innovation engine for a better tomorrow Q1 Earnings Call 2025 Stock Symbol: OTCQX:BLGO Standard Business Presentation 1
Slide 2: Safe Harbor Statement
All statements, other than statements of historical fact, included in this presentation and management’s explanation and discussion of this presentation, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of mana
Slide 3: Who we are
Who we are Innovators, Passionate about Driven by a mission scientists, engineers, sustainability and to make life better and entrepreneurs human health 3
Slide 4: What we do
What we do Best-in-class Focus on problems Aim for solutions for without good partnerships and cleantech problems solutions spin-outs to capitalize on our IP 4
Slide 5: Investing in… The BioLargo Innovation Engine
Investing in… The BioLargo Innovation Engine Engineering R&D 5
Slide 6: The Unseen Value of the BioLargo Portfolio
The Unseen Value of the BioLargo Portfolio • Unmatched technologies • Capital-conserving strategy • Highly qualified people • Driven for high impact $2.5B+ $1B+ $1B+ $100M+ These are targeted minimum future values for our portfolio companies, based on management’s modeling. This analysis does not in
Slide 7: Annual Revenue Run Rate and Q1 Highlights
ANNUAL REVENUE RUN RATE Q1 Highlights: $20 Revenue $18 • $3.27 million vs $4.76 million Q1 2024 (-31%) $16 Net loss • $1.92 million vs $0.76 million Q1 2024 $14 • Clyra had $1.40 million net loss compared with $0.55 million in Q1 2024, due to continued investment in $12 preparation for product launc
Slide 8: Net Stockholder's Equity
NET STOCKHOLDER'S EQUITY $7 $6 $5 $5.1 M $4 $3 $2 $1 $- $0 2018 2019 2020 2021 2022 2023 2024 Q1 OF 2025 $(1) $(2) $(3) Trends are not necessarily indicative of future performance 8
Slide 9: Unique Products
GETRID-~ OF THE a ELIMINATE IT PERMANENTLY WITH POOPH! Unique Products (sBiokargo 9
Slide 10: POOPH – Consumer pet odor product
POOPH – Consumer pet odor product Product marketed and sold by our partners, award-winning consumer product experts (Pooph, Inc.) ONM receives manufacturer’s margin and a royalty on sales Business strategy: ramp up sales and sell to a major consumer products company • ONM would receive 20% of exit 1
Slide 11: Clyra Medical Technologies
Clyra Medical Technologies • Unmatched claims in its product categories • FDA 510(k) cleared • Keystone has invested over $3 million in equipment and infrastructure in its manufacturing facilities • Clyra has invested over $2 million in molds, equipment and resources • Clyra has recently formalized
Slide 12: BioLargo Technologies / Cellinity
1 | BioLargo g TECHNOLOGIES 1} C=LLINITY
Slide 13: BioLargo's Cellinity
BioLargo’s Celli CELLINITY BATTERY SAFER Far safer because it has no risk of fire or explosion ty battery technology was created to provide a better option for battery energy storage than lithium-ion, empowering grid stability and storage of renewable energy. Compared to lithium-ion, Cellinity is: S
Slide 14: Compared to other Battery Chemistries
Compared to other Battery Chemistries Molten BioLargo Lithium-ion Nickel Specification Sodium-ion calcium Lead acid Battery (cobalt oxide) cadmium antimony (Liquid Sodium) Energy density (Wh/kg) 150-190 75-165 Low 30-50 45-80 552 Life cycle (down to 80% No loss in No loss in 500-1,000 2,000-6,000 20
Slide 15: Initially Targeting Two BESS Module Sizes
Initially Targeting Two BESS Module Sizes: 1-2 MWh ~25 KWh 15
Slide 16: Commercialization Pathway and Valuation Roadmap
Commercialization Pathway and Valuation Roadmap Underway Now! $43 million valuation – $1.5 billion NPV We are here (round A) Complete third-party Complete pilot Scale up cells manufacturing and battery validation Build Cellinity >$2.5 billion factories for future facility packs testing partners valu
Slide 17: A Broad-Spectrum, Low-Waste PFAS Capture Technology
A Broad-Spectrum, Low-Waste PFAS Capture Technology and Efficient Destruction 17
Slide 18: Why waste production matters
Why waste production Granular Activated matters Carbon Treatment Waste generated from treating 20,000 gallons of PFAS contaminated water ~1-2 lbs of 20-40,000 lbs of concentrate spent carbon 18
Slide 19: Q1 updates
Q1 updates • AEC system ready to ship to New Jersey project • Target August/September installation • Case study demonstrating 80% lifecycle cost savings of AEC process vs GAC for treating water • On April 28, 2025 the EPA released a press release reaffirming the agency's commitment to the reduction
Slide 20: Cost advantage when treating drinking water
Cost advantage when treating drinking water Why? • Far less treatment material needs to be replaced over time compared to GAC systems • Far less waste product generated in the course of water treatment • PFAS-laden waste generated in the course of water treatment is expensive 20
Slide 21: OTCQX: BLGO Contact
OTCQX: BLGO Contact: Dennis Calvert President & CEO BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683 (888) 400-2863 dc@BioLargo.com www.BioLargo.com 21